WO2021110181A3 - 可结合cd47的多肽及其应用 - Google Patents

可结合cd47的多肽及其应用 Download PDF

Info

Publication number
WO2021110181A3
WO2021110181A3 PCT/CN2021/075043 CN2021075043W WO2021110181A3 WO 2021110181 A3 WO2021110181 A3 WO 2021110181A3 CN 2021075043 W CN2021075043 W CN 2021075043W WO 2021110181 A3 WO2021110181 A3 WO 2021110181A3
Authority
WO
WIPO (PCT)
Prior art keywords
polypeptide
bind
seq
nos
sequence
Prior art date
Application number
PCT/CN2021/075043
Other languages
English (en)
French (fr)
Other versions
WO2021110181A2 (zh
Inventor
吴喜林
吴稚伟
苏艾荣
黄碧莲
Original Assignee
源道隆（苏州）医学科技有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 源道隆（苏州）医学科技有限公司 filed Critical 源道隆（苏州）医学科技有限公司
Publication of WO2021110181A2 publication Critical patent/WO2021110181A2/zh
Publication of WO2021110181A3 publication Critical patent/WO2021110181A3/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

提供一种可结合人CD47蛋白的多肽，包括3个互补决定区CDR1-3, CDR1序列为或包括SEQ ID NO:1-13所示序列之一，CDR2序列为或包括SEQ ID NO:14-24所示序列之一，CDR3序列为或包括SEQ ID N0:25-34 所示序列之一，可用于多种癌症的治疗。
PCT/CN2021/075043 2019-12-03 2021-02-03 可结合cd47的多肽及其应用 WO2021110181A2 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201911216842.X 2019-12-03
CN201911216842.XA CN110862455B (zh) 2019-12-03 2019-12-03 可结合cd47的多肽及其应用

Publications (2)

Publication Number Publication Date
WO2021110181A2 WO2021110181A2 (zh) 2021-06-10
WO2021110181A3 true WO2021110181A3 (zh) 2021-07-29

Family

ID=69658103

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2021/075043 WO2021110181A2 (zh) 2019-12-03 2021-02-03 可结合cd47的多肽及其应用

Country Status (2)

Country Link
CN (1) CN110862455B (zh)
WO (1) WO2021110181A2 (zh)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110862455B (zh) * 2019-12-03 2021-12-21 源道隆（苏州）医学科技有限公司 可结合cd47的多肽及其应用
CN111808193B (zh) * 2020-06-30 2022-04-05 源道隆（苏州）医学科技有限公司 可结合人cd38的纳米抗体及其应用
CN113583979B (zh) * 2021-08-03 2022-11-22 杭州荣谷生物科技有限公司 一种重组溶瘤痘苗病毒、制备方法及其用途

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109096395A (zh) * 2017-06-20 2018-12-28 华兰生物工程股份有限公司 阻断型cd47纳米抗体及其用途
CN110003335A (zh) * 2019-04-12 2019-07-12 深圳普瑞金生物药业有限公司 Cd47单域抗体的vhh链、cd47单域抗体、核苷酸序列及试剂盒
CN110144009A (zh) * 2018-02-14 2019-08-20 上海洛启生物医药技术有限公司 Cd47单域抗体及其用途
CN110256565A (zh) * 2019-08-02 2019-09-20 天津大学 抗cd47纳米抗体突变体及其应用
CN110862455A (zh) * 2019-12-03 2020-03-06 源道隆（苏州）医学科技有限公司 可结合cd47的多肽及其应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3470424A4 (en) * 2016-06-08 2020-03-04 Shanghai Jiaotong University School of Medicine SEQUENCE OF HEAVY CHAIN CONSTANT ANTIBODY REGION TO INCREASE AGONIST-ANTIBODY ACTIVITY

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109096395A (zh) * 2017-06-20 2018-12-28 华兰生物工程股份有限公司 阻断型cd47纳米抗体及其用途
CN110144009A (zh) * 2018-02-14 2019-08-20 上海洛启生物医药技术有限公司 Cd47单域抗体及其用途
CN110003335A (zh) * 2019-04-12 2019-07-12 深圳普瑞金生物药业有限公司 Cd47单域抗体的vhh链、cd47单域抗体、核苷酸序列及试剂盒
CN110256565A (zh) * 2019-08-02 2019-09-20 天津大学 抗cd47纳米抗体突变体及其应用
CN110862455A (zh) * 2019-12-03 2020-03-06 源道隆（苏州）医学科技有限公司 可结合cd47的多肽及其应用

Also Published As

Publication number Publication date
WO2021110181A2 (zh) 2021-06-10
CN110862455B (zh) 2021-12-21
CN110862455A (zh) 2020-03-06

Similar Documents

Publication Publication Date Title
WO2021110181A3 (zh) 可结合cd47的多肽及其应用
PH12018502623A1 (en) Anti-pd-l1 antibodies and uses thereof
PH12020551173A1 (en) Anti-pd-l1 antibodies and uses thereof
MX2023000781A (es) Anticuerpos monoclonales anti-cd47 humanizados, de raton, o quimericos.
HRP20201022T1 (hr) Potpuno ljudsko antitijelo protiv ljudskog cd137 i njegova uporaba
EP2471817A3 (en) Humanized antibody molecules specific for IL-31
SG151284A1 (en) Antibodies against ccr5 and uses thereof
JP2020500538A5 (zh)
NZ631007A (en) Anti-c5 antibodies having improved pharmacokinetics
JP2020515508A5 (zh)
IL295534A (en) Enhanced immunoglobulin variable sites
WO2011139974A3 (en) Anti-pai-1 antibodies and methods of use thereof
JP2020522261A5 (zh)
JP2016185981A5 (zh)
NZ605980A (en) Anti-fap antibodies and methods of use
WO2011051327A3 (en) Small antibody-like single chain proteins
NZ712765A (en) Antibodies that bind csf1r
JP2010502183A5 (zh)
JP2015534982A5 (zh)
WO2012048332A3 (en) A monoclonal antibody framework binding interface for meditopes, meditope delivery systems and methods for their use
RS54259B1 (en) HAVE AUTOANTITELA ACHIEVEMENTS
JP2017508475A5 (zh)
JP2017507131A5 (zh)
JP2017515815A5 (zh)
NZ628528A (en) Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21729785

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21729785

Country of ref document: EP

Kind code of ref document: A2